| The threat of antimicrobial resistance in developing countries: causes and control strategies JA Ayukekbong, M Ntemgwa, AN Atabe Antimicrobial Resistance & Infection Control 6, 1-8, 2017 | 1239 | 2017 |
| High rates of forward transmission events after acute/early HIV-1 infection BG Brenner, M Roger, JP Routy, D Moisi, M Ntemgwa, C Matte, JG Baril, ... The Journal of infectious diseases 195 (7), 951-959, 2007 | 882 | 2007 |
| HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture BG Brenner, M Oliveira, F Doualla-Bell, DD Moisi, M Ntemgwa, F Frankel, ... Aids 20 (9), F9-F13, 2006 | 276 | 2006 |
| Antiretroviral drug resistance in human immunodeficiency virus type 2 ML Ntemgwa, TA Toni, BG Brenner, RJ Camacho, MA Wainberg Antimicrobial agents and chemotherapy 53 (9), 3611-3619, 2009 | 95 | 2009 |
| Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors M Ntemgwa, BG Brenner, M Oliveira, D Moisi, MA Wainberg Antimicrobial agents and chemotherapy 51 (2), 604-610, 2007 | 78 | 2007 |
| The threat of antimicrobial resistance in developing countries: causes and control strategies. Antimicrob Resist Infect Control. 2017; 6: 47 JA Ayukekbong, M Ntemgwa, AN Atabe | 57 | 2018 |
| Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance HT Xu, JL Martinez-Cajas, ML Ntemgwa, D Coutsinos, FA Frankel, ... Retrovirology 6, 1-11, 2009 | 54 | 2009 |
| Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to … M Ntemgwa, MA Wainberg, M Oliveira, D Moisi, R Lalonde, V Micheli, ... Antimicrobial agents and chemotherapy 51 (11), 3861-3869, 2007 | 42 | 2007 |
| Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection TA Toni, EL Asahchop, D Moisi, M Ntemgwa, M Oliveira, B Masquelier, ... Antimicrobial agents and chemotherapy 53 (4), 1670-1672, 2009 | 35 | 2009 |
| Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2 ML Ntemgwa, TA Toni, BG Brenner, M Oliveira, EL Asahchop, D Moisi, ... Antimicrobial agents and chemotherapy 53 (2), 708-715, 2009 | 30 | 2009 |
| Benefits of an educational program for journalists on media coverage of HIV/AIDS in developing countries JL Martinez‐Cajas, CF Invernizzi, M Ntemgwa, SM Schader, ... Journal of the International AIDS Society 11 (1), 2-2, 2008 | 16 | 2008 |
| Discrepancies in assignment of subtype/recombinant forms by genotyping programs for HIV type 1 drug resistance testing may falsely predict superinfection M Ntemgwa, MJ Gill, BG Brenner, D Moisi, MA Wainberg AIDS research and human retroviruses 24 (7), 995-1002, 2008 | 16 | 2008 |
| Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1 TA Toni, BG Brenner, EL Asahchop, M Ntemgwa, D Moisi, MA Wainberg Antimicrobial agents and chemotherapy 54 (2), 907-911, 2010 | 15 | 2010 |
| COVID-19 compared to other epidemic coronavirus diseases and the flu JA Ayukekbong, ML Ntemgwa, SA Ayukekbong, EE Ashu, TA Agbor World Journal of Clinical Infectious Diseases 10 (1), 1-13, 2020 | 14 | 2020 |
| Point-of-care diagnosis and risk factors of infantile, rotavirus-associated diarrhoea in Calabar, Nigeria SE Nnukwu, SJ Utsalo, OG Oyero, M Ntemgwa, JA Ayukekbong African Journal of Laboratory Medicine 6 (1), 1-5, 2017 | 11 | 2017 |
| Neutralization kinetics of sensitive and resistant subtype B primary human immunodeficiency virus type 1 isolates D Davis, H Donners, B Willems, M Ntemgwa, T Vermoesen, ... Journal of medical virology 78 (7), 864-876, 2006 | 7 | 2006 |
| Near full-length genomic analysis of a novel subtype A1/C recombinant HIV type 1 isolate from Canada M Ntemgwa, TDA Toni, BG Brenner, JP Routy, D Moisi, M Oliveira, ... AIDS research and human retroviruses 24 (4), 655-659, 2008 | 6 | 2008 |
| Natural polymorphisms in the HIV-2 protease can accelerate time to development of resistance to Protease Inhibitors (PIs) M Ntemgwa, BG Brenner, M Oliveira, D Moisi, MA Wainberg Antimicrob Agents Chemother 51, 604-610, 2007 | 4 | 2007 |
| The impact of the journalist-to-journalist program on worldwide HIV awareness JL Martinez-Cajas, CF Invernizzi, M Ntemgwa, SM Schader, MA Wainberg Aids 22 (13), 1687-1688, 2008 | 3 | 2008 |
| Transmission events within risk groups following primary HIV-1 infection (PHI) in Quebec (1998-2005) BG Brenner, M Roger, D Moisi, C Matte, M Ntemgwa, JP Routy, M Legault, ... Antiviral Therapy 10 (4), S125-S125, 2005 | 3 | 2005 |
